Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aeterna Zentaris Inc T.AEZS

Alternate Symbol(s):  AEZS

Healthcare Biotechnology
Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company. The Company is developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company's lead product, macimorelin (Macrilen, Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The... see more

Recent & Breaking News (TSX:AEZS)

Aeterna Zentaris Announces Virtual 2022 Meeting of Shareholders and Urges Shareholders to Vote in Favor of the Proposed Share Consolidation

GlobeNewswire May 16, 2022

Aeterna Zentaris (TSX:AEZS) updates results from pre-clinical studies of its AIM Biologicals platform

Caroline Egan  May 12, 2022

Update on Positive Pre-Clinical Results from AIM Biologicals Development Program for the Potential Treatment of Parkinson's Disease

GlobeNewswire May 12, 2022

Aeterna Zentaris Reports First Quarter 2022 Financial Results and Provides Business Outlook

GlobeNewswire May 11, 2022

Aeterna Zentaris Abstract Accepted for Presentation at IMMUNOLOGY2022(TM), the Annual Event of the American Association of Immunologists

GlobeNewswire April 25, 2022

Aeterna Zentaris (TSX:AEZS) secures European patent for use of Macimorelin

Brieanna McCutcheon  April 19, 2022

Aeterna Zentaris Secures New European Patent Related to Use of Macimorelin for the Diagnosis of Growth Hormone Deficiency in Adults

GlobeNewswire April 19, 2022

JTC Team Announces Continuation of its Virtual Investor Spotlight Series with NASDAQ: AEZS, NASDAQ: CNSP, and NASDAQ: AREC

Accesswire April 13, 2022

Aeterna Zentaris to Participate at the Virtual Investor 2022 CEO Spotlight

GlobeNewswire April 12, 2022

Aeterna Zentaris Abstract Accepted for Presentation at 13th International Congress on Autoimmunity

GlobeNewswire April 11, 2022

Aeterna Zentaris Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Outlook

GlobeNewswire March 29, 2022

Aeterna Zentaris Provides Update on Ongoing Pivotal Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

GlobeNewswire March 21, 2022

Aeterna Zentaris Announces Expansion of Research Program with Julius-Maximilians-University Wuerzburg Aiming to Accelerate Development of Vaccine Programs

GlobeNewswire March 10, 2022

Aeterna Zentaris Announces Notice of Allowance for U.S. Patent Covering AEZS-150 for the Potential Treatment of Chronic Hypoparathyroidism

GlobeNewswire March 2, 2022

Aeterna Zentaris to Present at the 2022 BIO CEO & Investor Conference

GlobeNewswire February 7, 2022

Aeterna Zentaris Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

GlobeNewswire January 26, 2022

Aeterna Zentaris Provides Business Outlook and Outlines Pipeline Priorities

GlobeNewswire January 26, 2022

Aeterna Zentaris to Present at the Virtual Investor 2022 Top Picks Conference

GlobeNewswire January 20, 2022

JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th

Accesswire January 12, 2022

Aeterna Zentaris to Present at the H.C. Wainwright BioConnect Conference

GlobeNewswire January 5, 2022